The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The impact of extramedullary multiple myeloma on outcomes with ide-cel
Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, discusses the impact of extramedullary multiple myeloma (MM) on outcomes with idecabtagene vicleucel (ide-cel). He notes that patients with extramedullary disease have significantly worse outcomes, possibly due to differing disease biology. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
